Phaseline

Targets › CASR

CASR (Extracellular calcium-sensing receptor): drug programs, companies and trials

3 programs from 3 companies in 7 trials: 5 Phase 3, 2 Phase 2; Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.

G protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis. Senses fluctuations in the circulating calcium concentration: activated by elevated circulating calcium, leading to decreased parathyroid hormone (PTH) secretion in parathyroid glands (By similarity). (UniProt, P41180)

Open in Phaseline: the race on CASR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shaanxi Micot Pharmaceutical TechnologyMT1013
Calcimimetic agent (allosteric modulator of calcium-sensing receptor)
CASRPhase 3Secondary Hyperparathyroidism, Chronic Kidney Disease; Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on HemodialysisNov 2026
AmgenEtelcalcetide
Calcium sensing receptor agonist
CASRPhase 3Secondary HyperparathyroidismJun 2027
Calcilytix Therapeutics, Inc., a BridgeBio companyEncaleret
Calcimimetic agent; allosteric activator of the calcium-sensing receptor (CaSR)
CASRPhase 3Hypoparathyroidism; Autosomal Dominant Hypocalcemia (ADH); Autosomal Dominant Hypocalcemia Type 1 (ADH1)Jan 2028

Conditions

Secondary Hyperparathyroidism (2) Hypoparathyroidism (1) Autosomal Dominant Hypocalcemia (ADH) (1) Autosomal Dominant Hypocalcemia Type 1 (ADH1) (1) Secondary Hyperparathyroidism, Chronic Kidney Disease (1) Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis (1)

Modalities

small molecule (2), protein or peptide (1)

Companies

Amgen (1) Calcilytix Therapeutics, Inc., a BridgeBio company (1) Shaanxi Micot Pharmaceutical Technology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.